The costs of diabetes in 2020 and 2030 − A model analysis comparing innovative glucose lowering treatments in second line following European and American guidelines compared to current standard of care
A previous report estimated the long-term complications and societal costs of type 2 diabetes in 2020 and 2030 in Sweden (IHE Report 2015:1). That analysis showed that a more intensive treatment strategy, with more frequent health care contacts and a lower threshold for treatment change, reduces the risk of premature death and lead to fewer microvascular and macrovascular complications. By year 2030, the more intensive treatment strategy was cost-neutral.
This report (IHE Report 2016:9) updates the previous one by evaluating the effects from including DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors in second-line treatment. This treatment strategy is estimated to reduces the risk of premature death and decrease microvascular and macrovascular complications compared to a strategy similar to current standard of care in Sweden. At the current price level, the total societal cost was estimated to increase due to the use DPP-4 inhibitors, GLP-1 agonists and SGLT-2 inhibitors. When accounting for expected price reduction due to future patent expiries, the total societal cost was instead estimated to decrease by year 2030.
IHE Report 2016:9, IHE: Lund
Våra senaste IHE-rapporter
IHE Rapport / Ekonomisk utvärdering / 2026:8
Health-economic evaluation of extended age ranges and increased participation in breast cancer screening in four major European countries
IHE Rapport / RWE och register / 2026:3
Sjukdomsbördan vid astma i Sverige – en enkätstudie om resurskonsumtion, livskvalitet och vårdupplevelse
IHE Rapport / Policy / 2026:7